NCT05004415View on ClinicalTrials.gov

Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998)

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 28, 2021

Primary Completion Date

August 12, 2021

Study Completion Date

August 12, 2021

Conditions
Healthy Volunteer Study
Interventions
DRUG

AT-527 (R07496998)

Study participants will receive a single radiolabeled dose of 550 mg AT-527.

Trial Locations (1)

68502

Atea Study Site, Lincoln

Sponsors
All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

Atea Pharmaceuticals, Inc.

INDUSTRY